Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Intangibles (2016 - 2025)

Ironwood Pharmaceuticals (IRWD) has disclosed Intangibles for 6 consecutive years, with $2.0 million as the latest value for Q4 2025.

  • Quarterly Intangibles fell 28.67% to $2.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.0 million through Dec 2025, down 28.67% year-over-year, with the annual reading at $2.0 million for FY2025, 28.67% down from the prior year.
  • Intangibles hit $2.0 million in Q4 2025 for Ironwood Pharmaceuticals, down from $2.2 million in the prior quarter.
  • In the past five years, Intangibles ranged from a high of $4.1 million in Q2 2023 to a low of $2.0 million in Q4 2025.
  • Historically, Intangibles has averaged $3.1 million across 3 years, with a median of $3.1 million in 2024.
  • Biggest five-year swings in Intangibles: fell 20.09% in 2024 and later decreased 28.67% in 2025.
  • Year by year, Intangibles stood at $3.7 million in 2023, then decreased by 22.32% to $2.9 million in 2024, then dropped by 28.67% to $2.0 million in 2025.
  • Business Quant data shows Intangibles for IRWD at $2.0 million in Q4 2025, $2.2 million in Q3 2025, and $2.5 million in Q2 2025.